MAP2K7 and metastatic neoplasm: In patients with unresectable or metastatic disease, the therapeutic available strategies of targeted therapy (TT) with BRAF inhibitor (BRAFi) and MEK inhibitor (MEKi) and immune check-point inhibitors (ICIs) have led to a significant improvement in overall survival (OS) and progression-free survival (PFS).